Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.41 |
| ▸ | MMP2 | P08253 | 1/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP9 | P14780 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.36 |
| ▸ | FDPS | P14324 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GFER | P55789 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9889357 | 0.95 | MMP1 (0.37) | MMP1MMP2MMP3MMP9F2 | |
| Phosphoric Acid SCHEMBL17022775 | 0.71 | F2 (0.45) | MMP1MMP2MMP3MMP9F2 | |
| SCHEMBL15588635 | 0.69 | F2 (0.46) | F2MAPTALDH1A1 | |
| SCHEMBL24116790 | 0.67 | HPGD (0.37) | ALDH1A1TSHR | |
| Hydrochloric Acid SCHEMBL15560657 | 0.67 | F2 (0.43) | F2MAPTALDH1A1 | |
| SCHEMBL15588799 | 0.67 | F2 (0.50) | MMP1MMP2MMP3MMP9F2 | |
| SCHEMBL15588798 | 0.67 | F2 (0.50) | MMP1MMP2MMP3MMP9F2 | |
| SCHEMBL4586883 | 0.67 | — | — | |
| SCHEMBL24116789 | 0.66 | — | — | |
| SCHEMBL975100 | 0.65 | MMP1 (0.42) | MMP1MMP2MMP3MMP9FDPS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120141391-A1 | Use of creatine or creatine compounds for skin preservation | AVICENA GROUP, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20110085993-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | AVICENA GROUP, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20110021632-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | AVICENA GROUP, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-20110008272-A1 | Use of Creatine or Creatine Compounds for Skin Preservation | AVICENA GROUP, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20100329997-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | AVICENA GROUP, INC. (US) | 2010-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008272-A1 | Use of Creatine or Creatine Compounds for Skin Preservation | PC, CKMT1A; CKMT1B, CHEK1 | MMP1 1796/4885MMP2 1970/4885MMP3 862/4885 |
| US-20120141391-A1 | Use of creatine or creatine compounds for skin preservation | PC, CKMT1A; CKMT1B, CHEK1 | MMP1 1796/4885MMP2 1970/4885MMP3 862/4885 |
| US-20100329997-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | PC, CKMT1A; CKMT1B, CHEK1 | MMP1 1796/4885MMP2 1970/4885MMP3 862/4885 |
| US-20110021632-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | PC, CKMT1A; CKMT1B, CHEK1 | MMP1 1796/4885MMP2 1970/4885MMP3 862/4885 |
| US-20110085993-A1 | USE OF CREATINE OR CREATINE COMPOUNDS FOR SKIN PRESERVATION | PC, CKMT1A; CKMT1B, CHEK1 | MMP1 1796/4885MMP2 1970/4885MMP3 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.